Source: Health Products Regulatory Authority (IE) Revision Year: 2020 Publisher: Laboratoires Mayoly Spindler, 6 avenue de lEurope, BP 51, CHATOU Cedex, France
Cholurso 250 mg film-coated tablets.
| Pharmaceutical Form |
|---|
|
Film-coated tablet. White, round (11 mm diameter), biconvex film-coated tablet. |
Each tablet contains 250 mg of ursodeoxycholic acid.
Excipient with known effect: soya lecithin.
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Ursodeoxycholic acid |
The ursodeoxycholic acid converts lithogenic bile in non-lithogenic bile and gradually dissolves the cholesterol gallstones. |
| List of Excipients |
|---|
|
Core: Maize starch Film-coat: Lecithin (Soya) (E322) |
20, 30, 50, 60 or 100 tablets in blister packs (PVC / PVDC / Aluminium).
Not all pack sizes may be marketed.
Laboratoires Mayoly Spindler, 6 avenue de l’Europe, BP 51, CHATOU Cedex, France
PA1913/002/001
Date of first authorisation: 13 October 2017
Date of latest renewal: 19 December 2019
| Drug | Countries | |
|---|---|---|
| CHOLURSO | France, Ireland, United Kingdom |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
